BR Biopharma, Inc. (NASDAQ:BRBI – Get Free Report)’s share price traded up 0.3% during mid-day trading on Friday . The stock traded as high as $11.45 and last traded at $11.4860. Approximately 541 shares traded hands during trading, a decline of 16% from the average session volume of 641 shares. The stock had previously closed at $11.45.
Analyst Ratings Changes
Separately, Weiss Ratings upgraded shares of BR Biopharma from a “sell (e)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.
Read Our Latest Analysis on BR Biopharma
BR Biopharma Stock Performance
BR Biopharma (NASDAQ:BRBI – Get Free Report) last posted its earnings results on Tuesday, March 31st. The company reported $0.09 earnings per share (EPS) for the quarter. The firm had revenue of $25.95 million during the quarter.
BR Biopharma Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Friday, June 5th. Investors of record on Tuesday, May 19th were issued a dividend of $0.147 per share. This represents a $0.59 dividend on an annualized basis and a yield of 5.1%. The ex-dividend date of this dividend was Tuesday, May 19th.
Hedge Funds Weigh In On BR Biopharma
A hedge fund recently bought a new stake in BR Biopharma stock. Acuitas Investments LLC bought a new position in shares of BR Biopharma, Inc. (NASDAQ:BRBI – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 3,000 shares of the company’s stock, valued at approximately $45,000. BR Biopharma comprises 3.2% of Acuitas Investments LLC’s investment portfolio, making the stock its 7th largest position.
About BR Biopharma
BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.
Further Reading
- Five stocks we like better than BR Biopharma
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for BR Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BR Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
